Showing 6611-6620 of 8883 results for "".
- FDA Clears Sebacia Microparticles for Laser-Based Acne Treatmenthttps://practicaldermatology.com/news/fda-clears-sebacia-microparticles-for-laser-based-acne-treatment/2457603/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic
- Almirall and Evotec Form Dermatology Research Collaborationhttps://practicaldermatology.com/news/almirall-and-evotec-form-dermatology-research-collaboration/2457607/Alrimal and Evotec aim to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The two companies have for
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit
- ASDS 2018 Survey: Patients Spend About $100 Per Month on Skin Care Productshttps://practicaldermatology.com/news/asds-2018-survey-patients-spend-about-100-per-month-on-skin-care-products/2457608/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Der
- Inaugural World Eczema Day: GlobalSkin Launches International Movement for Eczema Sufferershttps://practicaldermatology.com/news/inaugural-world-eczema-day-globalskin-launches-international-movement-for-eczema-sufferers/2457611/To mark the first-ever Atopic Eczema Day, the International Alliance of Dermatology Patient Organizations (IADPO – also known as GlobalSkin) has launched AltogetherEczema, a new movement to elevate the urgent and unmet needs of the global eczema and atopic dermatitis community.
- First-Ever Molecular Study Shows African American Skin Reacts Differently to ADhttps://practicaldermatology.com/news/first-ever-molecular-study-shows-african-american-skin-reacts-differently-to-ad/2457612/African Americans are known to have greater treatment challenges with atopic dermatitis than European Americans and require higher doses of some medications to get relief, and now a new study suggests that differences in the molecular profile of their skin may be the reason. About 19 perc
- Allergan Launches Spotlyte: Digital Hub Will Educate Consumers About Medical Aesthetic Treatmentshttps://practicaldermatology.com/news/allergan-launches-spotlyte/2457615/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines.
- Mind the Gap: Disparity Between Urban and Rural Derms Widenshttps://practicaldermatology.com/news/mind-the-gap-disparity-between-urban-and-rural-derms-widens/2457618/The gap between dermatologists in urban and rural areas is widening across the United States, according to a new study of county-level data from 1995 to 2013 in JAMA Dermatology. Specifically, derm
- Ekwa Marketing Launches Affiliate Program, Offers Residual Income Opportunity for Medical Associationshttps://practicaldermatology.com/news/ewa-marketing-launches-affiliate-program-offers-residual-income-opportunity-for-medical-associations/2457622/Ekwa Marketing has launched its unique Ekwa Affiliate Program. Medical associations can simply place an online link to Ekwa’s innovative digital marketing products for doctors on their website and social media networks, and start receiving a passive i
- JW Pharmaceutical Signs Global Out-licensing Agreement for Atopic Dermatitis Drug Candidate with LEO Pharmahttps://practicaldermatology.com/news/jw-pharmaceutical-signs-global-out-licensing-agreement-for-atopic-dermatitis-drug-candidate-with-leo-pharma/2457626/JW Pharmaceutical and LEO Pharma A/S have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity